ERBB2 and breast carcinoma: To determine whether TP53 mutation has predictive value in HER2+ breast cancer patients, we first analyzed ctDNA sequencing results and the efficacy of pyrotinib in phase Ib, phase Ic, and phase II clinical trials led by our center.